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Guest Editorial
Adverse gene–environment interactions (G × E) probably influence 
most chronic diseases, including neurologic disorders and cancer. The 
genetic (G) contribution to different diseases varies, but several lines 
of evidence clearly show that non  genetic factors have high attribut­
able risks, often in the range of 80–90% (Willett 2002). The domi­
nance of non  genetic components highlights the importance of the 
environment (E) to chronic disease risks.
Genomic tools arising from the Human Genome Project (HGP), 
combined with bioinformatics studies, have allowed epidemiologists 
to examine the genetic component of chronic diseases. Genome­wide 
association studies offer glimpses of the roles that particular genes play 
in disease development. However, the genetic factors identified thus 
far have generally been of low penetrance (a few percent at most) and 
have mainly offered clues as to which G × E (and G × G) effects might 
be worth pursuing.
In contrast, the tools for quantitative assessment of exposures—
based on measurements of chemicals in air, water, food, and the 
human body—have changed little since the 1970s. The lack of 
high­throughput methods of exposure assessment has motivated 
epidemiolo  gists to rely upon self­reported data to categorize chemical 
exposures from envi­
ronmental, endog­
enous, and dietary 
sources. With the 
possible exceptions of 
smoking and alcohol 
consumption, such 
self­reports have been unreliable predictors of long­term exposure lev­
els and are poorly suited for detecting G × E effects. 
Although 30 years of investment in G now illuminates genetic 
determinants of diseases, we are still in the dark ages when it comes 
to quantifying E (i.e., human exposures). Recognizing the disparity in 
current knowledge between genes and environmental exposures, Wild 
(2005) defined the “exposome,” representing all environmental expo­
sures (including those from diet, lifestyle, and endogenous sources) 
from conception onward, as a quantity of critical interest to disease 
etiology. If we expect to have any success at identifying the effects of E, 
G, and G × E on chronic diseases, we must develop 21st­century tools 
to measure exposure levels in human populations. That is, we need an 
HGP­like commitment to quantify the exposome. 
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Elaborating the exposome will be challenging, but some promis­
ing analytical approaches are emerging from micro  fluidics, nano­
technologies, and mass spectrometry (MS). For example, a capil  lary 
lab­on­a­chip system has been developed to detect polycyclic aro­
matic hydro  carbons at parts­per­billion levels on the surface of Mars 
(Stockton et al. 2009), and surface enhanced Raman spectroscopy 
using silver nanoparticles has detected (and speciated) arsenic at 
parts­per­billion levels in water samples (Mulvihill et al. 2008). Both 
of these devices are portable, capable of high throughput, and can be 
adapted to other contaminants of interest. 
Technologic developments with liquid chromatography/tandem 
MS (LC­MS/MS) now motivate ultrasensitive measurements of pro­
tein adducts; these are excellent long­term biomarkers of exposure 
and internal dose for carcinogens (Rubino et al. 2009). Indeed, with 
National Institutes of Health Genes and Environment Initiative fund­
ing, we are using protein adductomics to profile human exposures 
in archived serum from cancer case–control studies. We ultimately 
envision an analytical platform to rapidly quantify protein adducts 
in much the same way that the DNA sequencer made possible the 
success of the HGP. Given the relentless improvements in MS sensi­
tivity, it is realistic to expect that this technology will be applied with 
a single drop of blood. In fact, our recent measure  ment of a benzene­
related adduct in dried blood spots opens the door to measure  ments 
of in utero chemical exposures, using archived neo  natal blood spots 
(Funk et al. 2008).
Simple and inexpensive monitoring methods can motivate reduc­
tions in exposures to toxic chemicals, as has been observed with inor­
ganic lead (Pirkle et al. 2005). Indeed, given people’s concerns about 
elevated levels of xeno  biotic chemicals in their bodies, commercial 
markets could ultimately develop for exposure sensors. However, 
without a regulatory mandate, we cannot rely upon the free mar­
ket alone to generate an exposure­sensing industry. We must focus 
instead upon the profound shortcomings that epidemiologists face 
in discovering environmental causes of chronic diseases without 
adequate exposure data. Facing a similar dilemma three decades ago, 
the HGP created several DNA sequencing centers to rapidly sequence 
the genome, and thereby created an infrastructure from which we 
still benefit. Imagine if we could build six or seven exposure biol­
ogy centers to quantify chemical exposures rapidly and at low cost. 
The impact such centers would have on our understanding of E and 
G × E as determinants of human disease would be extraordinary. 
True, an HGP­like effort for the environment would require a 
large investment. However, at a government cost of $2.7 billion (in 
$1991), HGP technologies will generate a projected $45 billion this 
year in sales. It does not require a great leap of faith to expect a simi­
lar multiplier from concerted action to quantify human exposures. 
As important sources of exposure are recognized and controlled, one 
can also anticipate reductions in morbidity and mortality that would 
translate into enormous savings in health care expenses.
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